Global Newsroom | CSL

CSL Seqirus Signs Long-Term Agreement with the Pan American Health Organization (PAHO) to Advance Pandemic Influenza Preparedness in Latin America and the Cari…

A new long-term pandemic preparedness agreement between CSL Seqirus and PAHO’s Regional Revolving Fund builds on the parties’ ...
Global Newsroom | CSL

Published Large U.S. Study Finds Comparable Effectiveness Between Adjuvanted and High-Dose Influenza Vaccines in Adults 65 Years and Older

Large cluster-randomized crossover study involving nearly 430,000 U.S. adults aged 65 years and older was published in the Journal of the American Medical Association (JAMA) Network ...
newsroom.csl

CSL announces rise in full year net profit

MELBOURNE, Aug. 18, 2025 /PRNewswire/ -- Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant ...
newsroom.csl

Global Newsroom

Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing,... Melbourne, 16 February 2026 CSL Seqirus, part ...
newsroom.csl

U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once ...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a ...
newsroom.csl

Our Commitment to the Hemophilia B Community: An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Availability

We are writing to share an important update on the availability of HEMGENIX ® (etranacogene dezaparvovec-drlb). CSL is currently experiencing a temporary global stockout of HEMGENIX ® that will result ...
newsroom.csl

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults

This historic approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine underscores CSL's promise to develop and deliver innovations when there is a public health need ...
newsroom.csl

World-class $1bn vaccine and antivenom manufacturing facility opens in Melbourne

Melbourne, Tuesday 2 December 2025 – Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing, opened CSL ...
newsroom.csl

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA ...
newsroom.csl

Australia’s Therapeutic Goods Administration (TGA) Approves Registration of CSL’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Hereditary Angioedema (HAE) Attacks

Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment modalities to ...
newsroom.csl

CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])

KING OF PRUSSIA, Pa., Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and ...
newsroom.csl

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal ...